Literature DB >> 27807074

Platelet Derived Growth Factor BB: A "Must-have" Therapeutic Target "Redivivus" in Ovarian Cancer.

Anca Maria Cimpean1, Ionut Marcel Cobec2, Raluca Amalia Ceaușu3, Roxana Popescu4, Anca Tudor5, Marius Raica3.   

Abstract

BACKGROUND: We aimed to validate PDGF-BB protein expression by RNAscope, a sensitive method for PDGF-BB mRNA evaluation on paraffin embedded (FFPE) specimens of ovarian tumors.
MATERIALS AND METHODS: Seventy-five FFPE ovarian cancer biopsies were assessed by immunohistochemistry followed by PDGF-BB mRNA RNAscope validation. RESULTS AND
CONCLUSION: Dual PDGF-BB expression in tumor and stromal cells have been observed, being highly suggestive for PDGF-BB mediated stromal-tumor cells reciprocal interaction in ovarian cancer (p=0.008). It seems that the nuclear expression of the PDGF-BB represents a negative prognostic factor in ovarian tumors. Being a controversial issue in the literature, PDGF-BB nuclear expression detected by immunohistochemistry was validated by RNAscope in situ hybridization. More than 65% of cases had PDGF-BB mRNA amplification, confirming immunohistochemical results. We herein validated PDGF-BB as a potential therapeutic and prognostic tool of ovarian cancer aggressiveness. Copyright
© 2016, International Institute of Anticancer Research (Dr. John G. Delinasios), All rights reserved.

Entities:  

Keywords:  PDGF-BB; RNAscope; ovarian carcinoma; therapy

Mesh:

Substances:

Year:  2016        PMID: 27807074      PMCID: PMC5219925          DOI: 10.21873/cgp.20014

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  29 in total

1.  Intraperitoneal Therapy for Ovarian Cancer.

Authors:  Franco M Muggia
Journal:  J Clin Oncol       Date:  2016-02-01       Impact factor: 44.544

2.  Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Authors:  Chunhua Lu; Mian M K Shahzad; Myrthala Moreno-Smith; Yvonne G Lin; Nicholas B Jennings; Julie K Allen; Charles N Landen; Lingegowda S Mangala; Guillermo N Armaiz-Pena; Rosemarie Schmandt; Alpa M Nick; Rebecca L Stone; Robert B Jaffe; Robert L Coleman; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2010-02-16       Impact factor: 4.742

3.  Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo.

Authors:  M A Versnel; M Haarbrink; A W Langerak; P A de Laat; A Hagemeijer; T H van der Kwast; L A van den Berg-Bakker; P I Schrier
Journal:  Cancer Genet Cytogenet       Date:  1994-03

4.  Estrogen regulates insulin-like growth factor 1, platelet-derived growth factor A and B, and their receptors in the vascular wall.

Authors:  Hanna Savolainen-Peltonen; Michael Loubtchenkov; Loubomir Petrov; Patrice Delafontaine; Pekka Häyry
Journal:  Transplantation       Date:  2004-01-15       Impact factor: 4.939

5.  Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma.

Authors:  Myungsun Shim; Cheryn Song; Sejun Park; Seung-Kwon Choi; Yong Mee Cho; Choung-Soo Kim; Hanjong Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-28       Impact factor: 4.553

6.  Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.

Authors:  Ursula A Matulonis; Suzanne Berlin; Percy Ivy; Karin Tyburski; Carolyn Krasner; Corrine Zarwan; Anna Berkenblit; Susana Campos; Neil Horowitz; Stephen A Cannistra; Hang Lee; Julie Lee; Maria Roche; Margaret Hill; Christin Whalen; Laura Sullivan; Chau Tran; Benjamin D Humphreys; Richard T Penson
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

7.  Incorporation of pazopanib in maintenance therapy of ovarian cancer.

Authors:  Andreas du Bois; Anne Floquet; Jae-Weon Kim; Joern Rau; Josep M del Campo; Michael Friedlander; Sandro Pignata; Keiichi Fujiwara; Ignace Vergote; Nicoletta Colombo; Mansoor R Mirza; Bradley J Monk; Rainer Kimmig; Isabelle Ray-Coquard; Rongyu Zang; Ivan Diaz-Padilla; Klaus H Baumann; Marie-Ange Mouret-Reynier; Jae-Hoon Kim; Christian Kurzeder; Anne Lesoin; Paul Vasey; Christian Marth; Ulrich Canzler; Giovanni Scambia; Muneaki Shimada; Paula Calvert; Eric Pujade-Lauraine; Byoung-Gie Kim; Thomas J Herzog; Ionel Mitrica; Carmen Schade-Brittinger; Qiong Wang; Rocco Crescenzo; Philipp Harter
Journal:  J Clin Oncol       Date:  2014-09-15       Impact factor: 44.544

Review 8.  Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives.

Authors:  Nicoletta Colombo; Pier Franco Conte; Sandro Pignata; Francesco Raspagliesi; Giovanni Scambia
Journal:  Crit Rev Oncol Hematol       Date:  2015-08-10       Impact factor: 6.312

Review 9.  Fit for the Eye: Aptamers in Ocular Disorders.

Authors:  Daniel W Drolet; Louis S Green; Larry Gold; Nebojsa Janjic
Journal:  Nucleic Acid Ther       Date:  2016-01-12       Impact factor: 5.486

10.  Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors.

Authors:  B M Kacinski; D Carter; E I Kohorn; K Mittal; R S Bloodgood; J Donahue; C A Kramer; D Fischer; R Edwards; S K Chambers
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug
View more
  4 in total

1.  Low Expression of 14-3-3beta Is Associated With Adverse Survival of Diffuse Large B-Cell Lymphoma Patients.

Authors:  Chaoping Li; Zhaoming Li; Mingzhi Zhang
Journal:  Front Med (Lausanne)       Date:  2019-10-30

2.  Novel application of electrochemical bipolar exfoliated graphene for highly sensitive disposable label-free cancer biomarker aptasensors.

Authors:  Shahrzad Forouzanfar; Iman Khakpour; Fahmida Alam; Nezih Pala; Chunlei Wang
Journal:  Nanoscale Adv       Date:  2021-08-12

3.  The expression of PDGF-BB predicts curative effect in locally advanced esophageal squamous cell carcinoma treated by radiotherapy.

Authors:  Puchun Er; Dong Qian; Wencheng Zhang; Baozhong Zhang; Hui Wei; Tian Zhang; Xi Chen; Yuwen Wang; Jingjing Zhao; Qi Wang; Qingsong Pang; Ping Wang
Journal:  Aging (Albany NY)       Date:  2020-04-24       Impact factor: 5.682

4.  In-Situ Integration of 3D C-MEMS Microelectrodes with Bipolar Exfoliated Graphene for Label-Free Electrochemical Cancer Biomarkers Aptasensor.

Authors:  Shahrzad Forouzanfar; Nezih Pala; Chunlei Wang
Journal:  Micromachines (Basel)       Date:  2022-01-09       Impact factor: 2.891

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.